Black Diamond Therapeutics (BDTX) Payables (2018 - 2021)
Historic Payables for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q3 2021 value amounting to $4.9 million.
- Black Diamond Therapeutics' Payables rose 6572.31% to $4.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $4.9 million, marking a year-over-year increase of 6572.31%. This contributed to the annual value of $2.5 million for FY2020, which is 2922.61% up from last year.
- Latest data reveals that Black Diamond Therapeutics reported Payables of $4.9 million as of Q3 2021, which was up 6572.31% from $5.0 million recorded in Q2 2021.
- Black Diamond Therapeutics' Payables' 5-year high stood at $5.0 million during Q2 2021, with a 5-year trough of $45000.0 in Q2 2020.
- Its 4-year average for Payables is $2.9 million, with a median of $2.9 million in 2020.
- The largest annual percentage gain for Black Diamond Therapeutics' Payables in the last 5 years was 1107777.78% (2021), contrasted with its biggest fall of 2153.77% (2021).
- Black Diamond Therapeutics' Payables (Quarter) stood at $416000.0 in 2018, then surged by 372.12% to $2.0 million in 2019, then grew by 29.23% to $2.5 million in 2020, then surged by 91.45% to $4.9 million in 2021.
- Its Payables was $4.9 million in Q3 2021, compared to $5.0 million in Q2 2021 and $4.6 million in Q1 2021.